{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:42Z","timestamp":1740144042070,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AIA International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40258-024-00912-1","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T19:02:32Z","timestamp":1725994952000},"page":"849-860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Public Preference for Off-Label Use of Drugs for Cancer Treatment and Relative Importance of Associated Adverse Events: A Discrete Choice Experiment and Best-Worst Scaling"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3462-4677","authenticated-orcid":false,"given":"Kailu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Man","family":"Shum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie Ho-Kwan","family":"Yam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza Lai-Yi","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eng-Kiong","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"issue":"2","key":"912_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/0976-500X.130046","volume":"5","author":"SK Gupta","year":"2014","unstructured":"Gupta SK, Nayak RP. Off-label use of medicine: perspective of physicians, patients, pharmaceutical companies and regulatory authorities. J Pharmacol Pharmacother. 2014;5(2):88\u201392.","journal-title":"J Pharmacol Pharmacother"},{"issue":"14","key":"912_CR2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1056\/NEJMp0802107","volume":"358","author":"RS Stafford","year":"2008","unstructured":"Stafford RS. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427\u20139.","journal-title":"N Engl J Med"},{"issue":"10","key":"912_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.mayocp.2012.04.017","volume":"87","author":"CM Wittich","year":"2012","unstructured":"Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982\u201390.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"912_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5306\/wjco.v7.i2.253","volume":"7","author":"D Leveque","year":"2016","unstructured":"Leveque D. Off-label use of targeted therapies in oncology. World J Clin Oncol. 2016;7(2):253\u20137.","journal-title":"World J Clin Oncol."},{"issue":"10","key":"912_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/archinternmed.2012.340","volume":"172","author":"T Eguale","year":"2012","unstructured":"Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R. Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med. 2012;172(10):781\u20138.","journal-title":"Arch Intern Med"},{"issue":"3","key":"912_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/jcpt.12507","volume":"42","author":"MM Saiyed","year":"2017","unstructured":"Saiyed MM, Ong PS, Chew L. Off-label drug use in oncology: a systematic review of literature. J Clin Pharm Ther. 2017;42(3):251\u20138.","journal-title":"J Clin Pharm Ther"},{"key":"912_CR7","doi-asserted-by":"publisher","unstructured":"De Souza JA, Duong YY. Off-label immunotherapy prescription: financial implications for payers and patients. J Clin Oncol. 2017;35(8S):6. https:\/\/doi.org\/10.1200\/JCO.2017.35.8_suppl.6","DOI":"10.1200\/JCO.2017.35.8_suppl.6"},{"issue":"1","key":"912_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","volume":"176","author":"T Eguale","year":"2016","unstructured":"Eguale T, Buckeridge DL, Verma A, Winslade NE, Benedetti A, Hanley JA, et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2016;176(1):55\u201363.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"912_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12887-019-1664-7","volume":"19","author":"M Mei","year":"2019","unstructured":"Mei M, Xu H, Wang L, Huang G, Gui Y, Zhang X. Current practice and awareness of pediatric off-label drug use in Shanghai, China: a questionnaire-based study. BMC Pediatr. 2019;19(1):281.","journal-title":"BMC Pediatr"},{"issue":"2","key":"912_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2125.2005.02397.x","volume":"60","author":"S Ekins-Daukes","year":"2005","unstructured":"Ekins-Daukes S, Helms PJ, Taylor MW, McLay JS. Off-label prescribing to children: attitudes and experience of general practitioners. Br J Clin Pharmacol. 2005;60(2):145\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"912_CR11","doi-asserted-by":"publisher","first-page":"lsac031","DOI":"10.1093\/jlb\/lsac031","volume":"9","author":"H Manley","year":"2022","unstructured":"Manley H, Sisk BA, Master Z, Scott CT. Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try. J Law Biosci. 2022;9(2):lsac031.","journal-title":"J Law Biosci"},{"issue":"1","key":"912_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40273-022-01198-8","volume":"41","author":"S Jiang","year":"2023","unstructured":"Jiang S, Ren R, Gu Y, Jeet V, Liu P, Li S. Patient preferences in targeted pharmacotherapy for cancers: a systematic review of discrete choice experiments. Pharmacoeconomics. 2023;41(1):43\u201357.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"912_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.2969","volume":"1","author":"A Anderson","year":"2018","unstructured":"Anderson A, Borfitz D, Getz K. Global public attitudes about clinical research and patient experiences with clinical trials. JAMA Netw Open. 2018;1(6): e182969.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"912_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","volume":"14","author":"H Collacott","year":"2021","unstructured":"Collacott H, Soekhai V, Thomas C, Brooks A, Brookes E, Lo R, et al. A systematic review of discrete choice experiments in oncology treatments. Patient. 2021;14(6):775\u201390.","journal-title":"Patient"},{"issue":"3","key":"912_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","volume":"3","author":"S Salas-Vega","year":"2017","unstructured":"Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 2017;3(3):382\u201390.","journal-title":"JAMA Oncol"},{"issue":"5","key":"912_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.13588","volume":"5","author":"C Shen","year":"2022","unstructured":"Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, et al. Overall survival in phase 3 clinical trials and the Surveillance, Epidemiology, and End Results Database in patients with metastatic colorectal cancer, 1986\u20132016: a systematic review. JAMA Netw Open. 2022;5(5): e2213588.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"912_CR17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","volume":"145","author":"P Arnaud-Coffin","year":"2019","unstructured":"Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. 2019;145(3):639\u201348.","journal-title":"Int J Cancer"},{"key":"912_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621639","volume":"11","author":"T Ouyang","year":"2021","unstructured":"Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, et al. Treatment-related serious adverse events of immune checkpoint inhibitors in clinical trials: a systematic review. Front Oncol. 2021;11: 621639.","journal-title":"Front Oncol"},{"key":"912_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2165\/00019053-200725030-00005","volume":"25","author":"DF Ossa","year":"2007","unstructured":"Ossa DF, Briggs A, McIntosh E, Cowell W, Littlewood T, Sculpher M. Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. Pharmacoeconomics. 2007;25:223\u201337.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"912_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s41669-019-00178-7","volume":"4","author":"HH Loong","year":"2020","unstructured":"Loong HH, Wong CKH, Leung LKS, Dhankhar P, Insinga RP, Chandwani S, et al. Cost effectiveness of PD-L1-based test-and-treat strategy with pembrolizumab as the first-line treatment for metastatic NSCLC in Hong Kong. Pharmacoecon Open. 2020;4(2):235\u201347.","journal-title":"Pharmacoecon Open."},{"issue":"11","key":"912_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111805","volume":"9","author":"J Veldwijk","year":"2014","unstructured":"Veldwijk J, Lambooij MS, de Bekker-Grob EW, Smit HA, de Wit GA. The effect of including an opt-out option in discrete choice experiments. PLoS ONE. 2014;9(11): e111805.","journal-title":"PLoS ONE"},{"issue":"1","key":"912_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12955-018-1013-9","volume":"16","author":"EM Stein","year":"2018","unstructured":"Stein EM, Yang M, Guerin A, Gao W, Galebach P, Xiang CQ, et al. Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States. Health Qual Life Outcomes. 2018;16(1):193.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"912_CR23","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008\u201319.","journal-title":"JAMA Oncol"},{"key":"912_CR24","unstructured":"Census and Statistics Department. Thematic Household Survey No. 67: information technology usage and penetration. 2019. https:\/\/www.statistics.gov.hk\/pub\/B11302672019XXXXB0100.pdf. Accessed 1 Sep 2024."},{"key":"912_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/00019053-200826080-00004","volume":"26","author":"E Lancsar","year":"2008","unstructured":"Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user\u2019s guide. Pharmacoeconomics. 2008;26:661\u201377.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"912_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/10705510701575396","volume":"14","author":"KL Nylund","year":"2007","unstructured":"Nylund KL, Asparouhov T, Muth\u00e9n BO. Deciding on the number of classes in latent class analysis and growth mixture modeling: a Monte Carlo simulation study. Struct Equ Model. 2007;14(4):535\u201369.","journal-title":"Struct Equ Model"},{"issue":"4","key":"912_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/0095798420930932","volume":"46","author":"BE Weller","year":"2020","unstructured":"Weller BE, Bowen NK, Faubert SJ. Latent class analysis: a guide to best practice. J Black Psychol. 2020;46(4):287\u2013311.","journal-title":"J Black Psychol"},{"issue":"7","key":"912_CR28","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40273-017-0506-4","volume":"35","author":"E Lancsar","year":"2017","unstructured":"Lancsar E, Fiebig DG, Hole AR. Discrete choice experiments: a guide to model specification, estimation and software. Pharmacoeconomics. 2017;35(7):697\u2013716.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"912_CR29","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/hec.870","volume":"13","author":"E Lancsar","year":"2004","unstructured":"Lancsar E, Savage E. Deriving welfare measures from discrete choice experiments: inconsistency between current methods and random utility and welfare theory. Health Econ. 2004;13(9):901\u20137.","journal-title":"Health Econ"},{"issue":"12","key":"912_CR30","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/hec.1437","volume":"18","author":"DA Marshall","year":"2009","unstructured":"Marshall DA, Johnson FR, Kulin NA, Ozdemir S, Walsh JM, Marshall JK, et al. How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ. 2009;18(12):1420\u201339.","journal-title":"Health Econ"},{"key":"912_CR31","unstructured":"2021 Population Census. Hong Kong. https:\/\/www.census2021.gov.hk\/en\/index.html. Accessed 1 Sep 2024."},{"issue":"12","key":"912_CR32","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/j.1524-4725.2010.01805.x","volume":"36","author":"BA Essers","year":"2010","unstructured":"Essers BA, Dirksen CD, Prins MH, Neumann HA. Assessing the public\u2019s preference for surgical treatment of primary basal cell carcinoma: a discrete-choice experiment in the south of the Netherlands. Dermatol Surg. 2010;36(12):1950\u20135.","journal-title":"Dermatol Surg"},{"issue":"4","key":"912_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266934","volume":"17","author":"H Iino","year":"2022","unstructured":"Iino H, Hashiguchi M, Hori S. Estimating the range of incremental cost-effectiveness thresholds for healthcare based on willingness to pay and GDP per capita: a systematic review. PLoS ONE. 2022;17(4): e0266934.","journal-title":"PLoS ONE"},{"key":"912_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.653450","volume":"9","author":"F Liu","year":"2021","unstructured":"Liu F, Hu H, Wang J, Chen Y, Hui S, Hu M. A study of patient preferences for the treatment of non-small cell lung cancer in western China: a discrete-choice experiment. Front Public Health. 2021;9: 653450.","journal-title":"Front Public Health"},{"issue":"6","key":"912_CR35","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1365-2125.2008.03290.x","volume":"66","author":"T Mukattash","year":"2008","unstructured":"Mukattash T, Millership J, Collier P, McElnay J. Public awareness and views on unlicensed use of medicines in children. Br J Clin Pharmacol. 2008;66(6):838\u201345.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"912_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1037\/0278-6133.22.3.235","volume":"22","author":"J Erblich","year":"2003","unstructured":"Erblich J, Montgomery GH, Valdimarsdottir HB, Cloitre M, Bovbjerg DH. Biased cognitive processing of cancer-related information among women with family histories of breast cancer: evidence from a cancer stroop task. Health Psychol. 2003;22(3):235.","journal-title":"Health Psychol"},{"key":"912_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-1-46","volume":"1","author":"E Ballatori","year":"2003","unstructured":"Ballatori E, Roila F. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes. 2003;1:1\u201311.","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"912_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.clinthera.2017.02.009","volume":"39","author":"L Eliasson","year":"2017","unstructured":"Eliasson L, de Freitas HM, Dearden L, Calimlim B, Lloyd AJ. Patients\u2019 preferences for the treatment of metastatic castrate-resistant prostate cancer: a discrete choice experiment. Clin Ther. 2017;39(4):723\u201337.","journal-title":"Clin Ther"},{"key":"912_CR39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3389\/fonc.2018.00535","volume":"8","author":"S Spaich","year":"2018","unstructured":"Spaich S, Kinder J, Hetjens S, Fuxius S, Gerhardt A, Sutterlin M. Patient preferences regarding chemotherapy in metastatic breast cancer: a conjoint analysis for common taxanes. Front Oncol. 2018;8:535.","journal-title":"Front Oncol"},{"issue":"1","key":"912_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-022-00357-7","volume":"8","author":"L Chaker","year":"2022","unstructured":"Chaker L, Razvi S, Bensenor IM, Azizi F, Pearce EN, Peeters RP. Hypothyroidism. Nat Rev Dis Primers. 2022;8(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"912_CR41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s10198-022-01438-w","volume":"23","author":"AC M\u00fchlbacher","year":"2022","unstructured":"M\u00fchlbacher AC, Sadler A, Jordan Y. Population preferences for non-pharmaceutical interventions to control the SARS-CoV-2 pandemic: trade-offs among public health, individual rights, and economics. Eur J Health Econ. 2022;23(9):1483\u201396.","journal-title":"Eur J Health Econ"},{"key":"912_CR42","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40271-017-0235-y","volume":"10","author":"DR Bien","year":"2017","unstructured":"Bien DR, Danner M, Vennedey V, Civello D, Evers SM, Hiligsmann M. Patients\u2019 preferences for outcome, process and cost attributes in cancer treatment: a systematic review of discrete choice experiments. Patient. 2017;10:553\u201365.","journal-title":"Patient"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00912-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-024-00912-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-024-00912-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T19:15:27Z","timestamp":1729019727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40258-024-00912-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1007\/s40258-024-00912-1","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"type":"print","value":"1175-5652"},{"type":"electronic","value":"1179-1896"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"18 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is supported by AIA International.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kailu Wang, Ho-Man Shum, Carrie Ho-Kwan Yam, Yushan Wu, Eliza Lai-Yi Wong, and Eng-Kiong Yeoh have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Survey and Behavioral Research Ethics Committee of the Chinese University of Hong Kong (Reference No.: SBRE-21-0764).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent was obtained from the participants prior to the survey.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data used in this study can be shared upon reasonable request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The codes used for this study can be shared upon reasonable request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"KW conceptualized, designed, and implemented the study, performed the data analysis, and drafted the manuscript. HMS and CHKY were in charge of investigation, data curation, and project administration. EKY supervised the study and made critical revisions to the manuscript. All authors edited and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}